Dyadic introduces novel method to produce synthetic cannabinoids and precursors utilizing c1 cell line production platform and patent pending process

Jupiter, fla., jan. 20, 2022 (globe newswire) -- dyadic international, inc. (“dyadic”, “we”, “us”, “our”, or the “company”) (nasdaq: dyai), a global biotechnology company focused on further improving, applying and deploying its proprietary c1-cell protein production platform to accelerate development, lower production costs, while enhancing commercial scales to improve access to biologic products in animal and human health, today announced its industrially proven c1-cells have been engineered to demonstrate the potential to manufacture therapeutically viable and commercially useful cannabis compounds including cannabidiol (cbd) and its precursors using synthetic biology. c1-cells have the potential to be an easy way to produce pure synthetic cannabinoids for commercial use cheaper and more effectively as compared to conventional extraction methods utilizing hemp and the marijuana plant, cannabis sativa.
DYAI Ratings Summary
DYAI Quant Ranking